Celecoxib for Back Muscle Pain

Evidence for NSAIDs in Back Pain

The American College of Physicians recommends NSAIDs, including celecoxib, as first-line pharmacologic treatment for acute and chronic low back pain when nonpharmacologic approaches are insufficient 1
For acute low back pain, NSAIDs demonstrate clear superiority over placebo with a relative risk of 1.24 for global improvement and 1.29 for not requiring additional analgesics after 1 week of therapy 2, 3
For chronic low back pain, NSAIDs have been shown superior to placebo in higher-quality trials, though the evidence base specifically for celecoxib in low back pain is limited 2, 3

No evidence demonstrates that celecoxib is superior to other NSAIDs for back pain relief—the Cochrane review found no NSAID superior to others for pain relief in 24 comparative trials 2, 3
Most trials of NSAIDs for low back pain were only 2 weeks in duration; only 6 of 51 trials exceeded 2 weeks (longest was 6 weeks) 2, 3
The major limitation is sparse long-term data—only 6 of 51 NSAID trials for low back pain exceeded 2 weeks duration, making long-term benefit-risk assessment difficult 2, 3
Celecoxib is not disease-modifying for most back pain, though one trial suggested continuous celecoxib treatment may retard radiographic progression in ankylosing spondylitis at 2 years 4
For back pain with sciatica/radiculopathy, NSAIDs including celecoxib show no difference from placebo on effectiveness outcomes, making them a poor choice for predominantly radicular symptoms 2, 3

The American College of Physicians systematic review found that NSAIDs demonstrated minimal benefit in the two trials evaluating radicular pain, with small and inconsistent effects on pain and no assessment of functional improvement 5, 6
No particular NSAID has been shown superior to others for pain relief, with 21 trials comparing different NSAIDs for acute low back pain and 6 trials for chronic low back pain finding no clear differences 5

The American College of Rheumatology explicitly states no recommendation for any particular NSAID as the preferred choice, with 100% agreement among experts, and head-to-head trials comparing celecoxib to diclofenac and ketoprofen showed no efficacy differences 7

COX-2 selective NSAIDs (celecoxib) have a lower risk for adverse effects than nonselective NSAIDs (naproxen) with a risk ratio of 0.83 (95% CI 0.70 to 0.99) 5
Cardiovascular, gastrointestinal, and renal risks should be taken into account when prescribing any NSAID 8

If no contraindications exist, either celecoxib or naproxen is acceptable based on cost and patient preference, according to the American College of Physicians and the American College of Rheumatology 5, 7